Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2383]

How will ASCO combat cancer disparities?

Dr Eduardo Cazap, Dr Richard Schilsky

How will ASCO combat cancer disparities? ( Dr Eduardo Cazap, Dr Richard Schilsky )

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

Prof Max Topp - University of Würzburg, Würzburg, Germany

$Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )$

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy...

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

$CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )$

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

Cancer care in low and middle income countries

Dr Gouri Shankar Bhattacharyya - FORTIS Hospital, Kolkata, India

Cancer care in low and middle income countries ( Dr Gouri Shankar Bhattacharyya - FORTIS Hospital, Kolkata, India )

Surveying cancer patients' mental health and financial problems

Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa

Surveying cancer patients' mental health and financial problems ( Dr Daniel Vorobiof - Sandton Oncology Centre, Sandton, South Africa )

Implementing better cancer diagnosis in low and middle income countries

Dr Gilberto Lopes - University of Miami and the Miller School of Medicine...

Implementing better cancer diagnosis in low and middle income countries ( Dr Gilberto Lopes - University of Miami and the Miller School of Medicine, Miami, USA )

Use of maintenance therapy following ASCT and real world treatment patterns in...

Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold

Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma ( Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold )

More from ecancer